Quote | Oric Pharmaceuticals Inc. (NASDAQ:ORIC)
Last: | $10.27 |
---|---|
Change Percent: | -6.55% |
Open: | $11.63 |
Close: | $10.99 |
High: | $11.96 |
Low: | $10.22 |
Volume: | 262,496 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | Oric Pharmaceuticals Inc. (NASDAQ:ORIC)
2024-06-13 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 04:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Oric Pharmaceuticals Inc. (NASDAQ:ORIC)
Subject | By | Source | When |
---|---|---|---|
Price gaining last up | makinezmoney | investorshub | 06/20/2023 8:48:31 AM |
Price now | makinezmoney | investorshub | 05/30/2023 4:54:44 AM |
Price gaining | TheFinalCD | investorshub | 05/30/2023 12:36:19 AM |
$ORIC LOOKS LIKE $6 COMING | TheFinalCD | investorshub | 12/23/2022 7:14:12 PM |
$ORIC: Tapped $5.40....... still got steam | makinezmoney | investorshub | 12/23/2022 2:49:12 PM |
News, Short Squeeze, Breakout and More Instantly...
Oric Pharmaceuticals Inc. Company Name:
ORIC Stock Symbol:
NASDAQ Market:
Oric Pharmaceuticals Inc. Website:
2024-06-13 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 04:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best...